drugset / Trial / NCT03192579
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial
RandomizedParallel-groupDouble-blindTreatment
Summary
This study aim to evaluate whether intensive lipid lowering therapy may improve the clinical outcomes in coronary artery disease patients with in-stent neoatherosclerosis, in comparison with standard therapy.
Timeline
- Start
- 2013-07-26
- Primary completion
- 2017-06-02
- Completion
- 2017-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eicosapentaenoic acid | Small molecule | 1800 mg | — |
| Subject | Rosuvastatin | Small molecule | 2.5 mg | — |
| Subject | Rosuvastatin | Small molecule | 5 mg | — |
| Subject | Rosuvastatin | Small molecule | 10 mg | — |
| Subject | Rosuvastatin | Small molecule | 20 mg | — |